Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRX-101 (Sulodexide) in Type 2 Diabetic Nephropathy
NCT00462202Phase 3Terminated
- Sponsor
- Keryx Biopharmaceuticals, Inc.
- Start
- Apr 2007
- Primary completion
- Mar 2008
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sulodexide in diabetic nephropathy (DN), sponsored by Keryx Biopharmaceuticals, Inc. Primary endpoint: Albumin/Creatinine Ratio at 1 year. Started Apr 2007; status: terminated.
02
Drugs
sulodexide
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00462202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00462202.